COVID-19 update: Sanofi enters vaccine race with BARDA collaboration; plus J&J-BARDA expansion, clinical and diagnostic advances, and more

With support from HHS, Sanofi is adapting the platform behind its approved flu vaccine to develop a COVID-19 vaccine.

A Sanofi (Euronext:SAN; NASDAQ:SNY) spokesperson told BioCentury the company will, at its own expense, develop a virus bank and the Biomedical Advanced Research and Development Authority (BARDA) will fund a "research lot that ensures reproducible testing and production of recombinant vaccines." The two will collaborate to choose a COVID-19 strain against which the vaccine will be developed...